Janssen Announces Erdafitinib Improved Overall Survival

Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with...

Related Keywords

France ,Paris ,France General ,Belgium ,Beerse ,Region Flamande ,United States ,Chicago ,Illinois ,Saclay ,American ,Milenkovic Petronic ,Sipetic Grujicics Urothelial ,Janssen Cilag Gm ,Yohann Loriot ,Kiran Patel ,Institut Gustave Roussy ,Janssen Pharmaceutica ,Clinical Development ,Companies Of Johnson ,Astex Therapeutics ,Johnson ,Drug Administration ,Janssen Pharmaceutical Companies ,Janssen Research Development In Phase ,Janssen Research Development ,Janssen Pharmaceutical Companies Of Johnson ,Astex Announces New Drug Discovery Alliance ,American Society Of Clinical Oncology ,National Cancer Institute ,University Of Paris ,None Of The Janssen Pharmaceutical Companies ,Late Breaking Presentation Session ,Clinical Oncology ,Annual Meeting ,Hazard Ratio ,Relative Risk ,Final Results ,Evaluating Erdafitinib ,Cetrelimab Combination ,Vice President ,Solid Tumors ,Janssen Research ,Bacillus Calmette Gu ,Astex Therapeutics Limited ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Metastatic Urothelial Carcinoma ,Fibroblast Growth Factor Receptor Alterations ,Erdafitinib Compared With Vinflunine ,Participants With Advanced Urothelial Cancer ,Selected Fibroblast Growth Factor Receptor ,Gene Aberrations ,Text View ,Participants With Metastatic ,Locally Advanced Urothelial ,Locally Advanced Urothelial Cancer ,Participants With Advanced Solid Tumors ,Fibroblast Growth Factor Receptor ,Gene Alterations ,Locally Advanced ,Metastatic Urothelial ,Erdafitinib Versus Investigator Choice ,Participants Who Received Bacillus Calmette Gu ,Accessed May ,Urothelial Carcinoma ,Sipetic Grujicic ,Transduct Target Ther ,Rev Clin ,Bladder Cancer Prognosis ,Survival Rates ,Janssen Emea ,